SERPASIL-ESIDRIX #1
LOE ApproachingNDAORALTABLET
Approved
May 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERPASIL-ESIDRIX #1 is a fixed-dose oral tablet combining reserpine and hydrochlorothiazide, approved in 1959 for hypertension management. This combination product represents an early polypharmacy approach to blood pressure control through dual mechanisms. The product is a small-molecule antihypertensive indicated for patients requiring combination therapy.
LOE Approaching
This legacy product faces significant competitive pressure (30% intensity) with minimal active development, indicating a small, maintenance-focused commercial team managing decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SERPASIL-ESIDRIX #1 offers limited career growth; roles are primarily defensive/maintenance-focused on a shrinking market with zero clinical innovation or launch opportunity. This assignment is suitable for early-career professionals seeking operational experience on a stable product, or as a transition role, but not recommended for those seeking dynamic commercial or R&D growth.
Brand Manager (generic/maintenance)
Worked on SERPASIL-ESIDRIX #1 at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.